免费早鸟票,200 张限量领取2025 年 9 月 22 日医麦客新闻 eMedClub News2025 年上半年,诺和诺德司美格鲁肽销售额突破 166 亿美元,首次超越默沙东 Keytruda,登顶“全球药王”。这一数字既印证 GLP-1 类药物在减重与代谢领域的统治级表现,更凸显减重万亿市场的爆发力。为捍卫减重王者地位,诺和诺德近期与 Replicate Bioscience 达成最高 ...
Source Link免费早鸟票,200 张限量领取2025 年 9 月 22 日医麦客新闻 eMedClub News2025 年上半年,诺和诺德司美格鲁肽销售额突破 166 亿美元,首次超越默沙东 Keytruda,登顶“全球药王”。这一数字既印证 GLP-1 类药物在减重与代谢领域的统治级表现,更凸显减重万亿市场的爆发力。为捍卫减重王者地位,诺和诺德近期与 Replicate Bioscience 达成最高 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.